Pulmatrix Inc, a clinical stage Massachusetts-based biotechnology company developing a new, inhaled dry powder platform with new generation inhaled therapeutics, said the Phase 1b study on its new drug candidate, PUR1800, showed positive results. PUR1800 is a narrow spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation with iSPERSE– a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and absorption. The Phase 1b study analysed 18 subjects to find that PUR 1800 was well-tolerated with no safety signals.